- Report
- March 2025
- 175 Pages
Global
From €4304EUR$4,490USD£3,597GBP
- Report
- May 2024
- 134 Pages
Global
From €6230EUR$6,499USD£5,206GBP
- Report
- January 2024
- 200 Pages
Global
From €3978EUR$4,150USD£3,324GBP
- Report
- April 2024
- 86 Pages
Global
From €3500EUR$3,911USD£3,027GBP
- Report
- January 2024
- 86 Pages
Global
From €3500EUR$3,911USD£3,027GBP
- Report
- April 2025
- 50 Pages
Global
From €2540EUR$2,650USD£2,123GBP
Abacavir is an immune disorder drug used to treat HIV infection. It is a nucleoside reverse transcriptase inhibitor (NRTI) that works by blocking the action of the enzyme reverse transcriptase, which is needed for the virus to replicate. Abacavir is usually taken in combination with other antiretroviral drugs to help control HIV infection. It is available in both oral and injectable forms.
Abacavir is used to treat HIV infection in adults and children over the age of three months. It is also used to reduce the risk of HIV transmission from mother to child during pregnancy and delivery. Abacavir is generally well tolerated, but can cause side effects such as nausea, vomiting, and rash.
The abacavir market is highly competitive, with several major players offering products. Some of the leading companies in the market include Gilead Sciences, Bristol-Myers Squibb, Merck & Co., and GlaxoSmithKline. These companies are continuously developing new products and expanding their product portfolios to meet the needs of patients. Show Less Read more